TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you! 📣

And if you like these newsletters and think a friend or colleague would benefit, please share this with them! ♻️

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a [Paywall] tag for any news stories behind one.

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE GOOD
Business Development

Eli Lilly buys neurodegerative disease asset from QurAlis
$45M upfront, $577M biobucks
Antisense oligonucleotide, amyotrophic lateral sclerosis, frontotemporal dementia - Read more

THE GOOD
Clinical Trials

Agios Pharmaceuticals blood-disorder Ph3 success
Small molecule, thalassemia - Read more

Arrowhead Pharmaceuticals rare disease Ph3 win
RNAi, familial chylomicronemia syndrome - Read more

AstraZeneca immunotherapy wards off death in rare lung cancer
Monoclonal antibody, limited stage small cell lung cancer - Read more

Bristol Myers Squibb Ph3 data looks promising, though progression-free survival leaves doubt
Small molecule, lung cancer - Read more

Caribou Biosciences “encouraging” partial HLA matching allogeneic cell therapy Ph1 data
Cell therapy, allogeneic, CAR-T, lymphoma, cancer - Read more

GenFleet Therapeutics touts Ph2 data, first line combo therapy for lung cancer
Small molecule, antibody, combination therapeutics, lung cancer - Read more

Intellia Therapeutics CRISPR Ph1 data shows HAE attack reduction up to 2+ years
CRISPR, gene-editing, hereditary angioedema - Read more

Jazz Pharma showcases “unprecedented” long-term Ph2b data
Bispecific antibody, advanced biliary tract cancer - Read more

Purple Biotech’s positive interim Ph2 data for pancreatic cancer
Monoclonal antibody, pancreatic cancer - Read more

Sanofi’s positive Ph3 data for transplant-ineligible multiple myeloma
Monoclonal antibody, blood cancer - Read more

Structure Therapeutics sheds weight but packs on stock price pounds (dollars) with new Ph2a data reveal
Oral GLP-1, weight loss - Read more

Tagrisso shows-off impressive Ph3 lung cancer data
Small molecule, lung cancer - Read more

Takeda, Pfizer’s collab bears positive Ph3 fruit
Antibody-drug conjugate, lymphoma, cancer - Read more

No sleeping on Takeda’s positive Ph2b narcolepsy data
Small molecule, narcolepsy type 1 - Read more

YourChoice Therapeutics erects positive Ph1a data for male contraceptive
Small molecule, male contraceptive - Read more

THE GOOD
Company Launches

Freeze your body until a cure is available? That’s the idea behind Cradle Healthcare
Cryogenics, life extension - Read more [Paywall]

THE GOOD
Fundraises

Brandon Capital closes 6th round, A$270 million (US$180 million)
Life science venture capital - Read more

Sinopia Biosciences SBIR grant (amount undisclosed)
Computational drug discovery, omics, machine learnings - Read more

Punto Health Pre-Seed raise, £550K ($704K)
Digital health, Alzheimer’s, dementia - Read more

Rhea follow-on funding (amount undisclosed)
Reproductive health, clinical services - Read more

THE GOOD
IPOs

Rapport Therapeutics prices upcoming IPO
Expected $136M raise via 8 million shares at $16-18/share + $18M private
Small molecule, CNS disorders - Read more

THE GOOD
Mergers & Acquisitions

BD buys Edwards Lifesciences, $4.2B
Patient monitoring, medical device, sensors - Read more

THE GOOD
Opinions

Merck Research Laboratories CMO appears subdued regarding Summit Therapeutics Keytruda head-to-head upset
Bispecific antibody, lung cancer - Read more

THE GOOD
Research

Delfi Diagnostics publishes liquid biopsy test research & announces Merck Global Health Innovation Fund investment (amount undisclosed)
Liquid biopsy, lung cancer screening - Read more

Bristol Myers Squibb sponsored research; pre-surgery immunotherapy treatment for melanoma leads to better outcomes
Monoclonal antibody, melanoma, skin cancer - Read more

THE GOOD
Strategic Plans

Merck & Co outlines plans for a post-Keytruda future - with one aspect being mRNA
mRNA, cancer vaccine, melanoma, skin cancer - Read more

THE UGLY
Clinical Trials

Isotope shortage forces Bristol Myers Squibb acquisition RayzeBio to halt Ph3 recruitment
Radiopharmaceuticals, gastroenteropancreatic neuroendocrine tumors, cancer - Read more

THE UGLY
Lawsuits

With Zantac suit cleared to proceed, GSK gets 10% shaved off its stock price
Small molecule, heartburn, cancer, alleged carcinogen - Read more

THE UGLY
Politics & Policy

Bipartisan tensions flare as Dr. Fauci testifies on Covid-19 pandemic origin
Covid-19, pandemic - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 250+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.